Ixekizumab + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Genital Psoriasis
Conditions
Genital Psoriasis, Psoriasis
Trial Timeline
Apr 1, 2016 → Feb 21, 2018
NCT ID
NCT02718898About Ixekizumab + Placebo
Ixekizumab + Placebo is a phase 3 stage product being developed by Eli Lilly for Genital Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT02718898. Target conditions include Genital Psoriasis, Psoriasis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04285229 | Phase 3 | Completed |
| NCT03364309 | Phase 3 | Completed |
| NCT03129100 | Phase 3 | Completed |
| NCT02757352 | Phase 3 | Completed |
| NCT02696798 | Phase 3 | Completed |
| NCT02718898 | Phase 3 | Completed |
| NCT02584855 | Phase 3 | Completed |
| NCT02513550 | Phase 3 | Completed |
| NCT01107457 | Phase 2 | Completed |
Competing Products
20 competing products in Genital Psoriasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tideglusib | AMO Pharma | Pre-clinical | 15 |
| Tideglusib + Placebo | AMO Pharma | Phase 2/3 | 57 |
| Tideglusib | AMO Pharma | Phase 2/3 | 57 |
| Fulvestrant + Abemaciclib | Eli Lilly | Phase 2 | 52 |
| EDIT-101 | Editas Medicine | Phase 1/2 | 33 |
| Gemcitabine + liposomal doxorubicin | Eli Lilly | Phase 3 | 77 |
| Tildacerfont/Placebo | Spruce Biosciences | Phase 2 | 44 |
| SPR001 | Spruce Biosciences | Phase 2 | 44 |
| SPR001 | Spruce Biosciences | Phase 2 | 44 |
| Tildacerfont/Placebo | Spruce Biosciences | Phase 2 | 44 |
| Tildacerfont | Spruce Biosciences | Phase 2 | 44 |
| ASP2151 + Placebo | Astellas Pharma | Phase 1 | 33 |
| ASP2151 + valacyclovir + Placebo | Astellas Pharma | Phase 2 | 52 |
| Tildrakizumab 100 mg + Placebo | Sun Pharmaceutical | Phase 3 | 77 |
| Topical NO + Placebo | Kyowa Kirin | Phase 2 | 52 |
| KW-3357 | Kyowa Kirin | Phase 1 | 33 |
| Gemcitabine + Paclitaxel + Carboplatin | Eli Lilly | Phase 3 | 77 |
| Daratumumab | Johnson & Johnson | Phase 2 | 52 |
| Risankizumab + Placebo for Risankizumab | AbbVie | Approved | 85 |
| Ropivacaine + Epinephrine + Decadron + Clonidine + Propofol | Merck | Phase 3 | 77 |